PC
Percy H. Carter
Chief Scientific Officer

Percy H. Carter insider trades: Blueprint Medicines (BPMC) stock sales

Chief Scientific Officer, Blueprint Medicines Last trade Jul 3, 2025 16 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
9
Open-market trades
since 2022
1
Company
last trade 2025

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Percy reports to the SEC

Open-market buys and sales

9 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jul 3, 2025BPMC↓ Sell$135K
Jun 3, 2025BPMC↓ Sell$340K
Mar 5, 2025BPMC↓ Sell$313K
Jun 5, 2024BPMC↓ Sell$421K
Jun 3, 2024BPMC↓ Sell$259K
Mar 7, 2024BPMC↓ Sell$207K
Jun 5, 2023BPMC↓ Sell$120K
Mar 6, 2023BPMC↓ Sell$35K
Jun 6, 2022BPMC↓ Sell$114K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About Percy H. Carter's insider trades

Percy H. Carter is Chief Scientific Officer at Blueprint Medicines (BPMC). Since Jun 6, 2022, Percy has reported no open-market purchases and 9 sales worth $1.9M on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (7 filings), other transactions (1 filing), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every BPMC insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.